scPharmaceuticals Inc. (SCPH) NASDAQ
5.67
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.67
+0(+0.00%)
Currency In USD
| Previous Close | 5.67 |
| Open | 5.67 |
| Day High | 5.67 |
| Day Low | 5.67 |
| 52-Week High | 6.28 |
| 52-Week Low | 1.94 |
| Volume | 10.9M |
| Average Volume | 1.45M |
| Market Cap | 302.2M |
| PE | -3.13 |
| EPS | -1.81 |
| Moving Average 50 Days | 5.34 |
| Moving Average 200 Days | 3.86 |
| Change | 0 |
Data not available
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
GlobeNewswire Inc.
Oct 07, 2025 1:02 PM GMT
DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is expected to di
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
GlobeNewswire Inc.
Aug 25, 2025 11:31 AM GMT
Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per
scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111
GlobeNewswire Inc.
Aug 14, 2025 12:30 PM GMT
BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, announced today that it ha